Prashant Mehta, Senior Consultant and Assistant Professor in the Department of Medical Oncology/Hematology-Oncology and Bone Marrow Transplantation at the Amrita Hospital, Faridabad, shared a post by Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University on X, addding:
“Should we consider consolidative Allo in high IPI DLBCL post CAR-T ?
In the quoted study , the survival benefit of CART was significant in patients with low/low-intermediate IPI (OS HR 0.43, 95% CI 0.31-0.60), but not observed in high-risk patients. Elevated LDH eliminated the PFS advantage of CART over alloSCT. Do poorer outcomes after CART in patients with high-risk disease support early preparation for alloSCT for eligible patients.”
Quoting Mostafa Faisal
“The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL) | Bone Marrow Transplantation.”
Title: The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Authors: Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, Federico Stella, Ron Ram, Nicolaus Kröger, Luca Castagna, Thomas Pabst, Gerald G. Wulf, Alejandro Martin Garcia-Sancho, Carlos Solano, Matthias Stelljes, Hans C. Reinhardt, Edouard Forcade, Malte von Bonin, Inken Hilgendorf, Joaquin Martínez López, Wolfgang Bethge, Ali Bazarbachi, Anna Sureda, Norbert Schmitz, Bertram Glass
Read The Full Article
Other articles about CAR T-cell therapy on OncoDaily.